Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases

Fig. 1

Interferon (IFN) score in systemic lupus erythematosus (SLE) patients and multiple sclerosis (MS) patients who received 3 months of IFNβ treatment. Average expression levels of 23 interferon response genes (IRGs) show a comparable range for the majority of SLE patients and IFNβ-treated MS patients. SLE and IFNβ-treated MS patients with an IFN score between 2.5 and 4.0 (gray area) were selected for the initial comparison of the composition of the IFN signature. Patients with a type I interferon signature and an IFN score above 4.0 or below 2.5 were used as an additional cohort. HC healthy controls

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us